|Bid||270.64 x 800|
|Ask||271.44 x 800|
|Day's Range||268.31 - 272.04|
|52 Week Range||185.20 - 275.15|
|Beta (5Y Monthly)||0.97|
|PE Ratio (TTM)||49.65|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||2.52 (0.93%)|
|Ex-Dividend Date||Jun 29, 2021|
|1y Target Est||274.09|
Stryker CEO Kevin Lobo joins Julie Hyman, Brian Sozzi and Myles Udland to discuss the medical tech company’s second-quarter results, including how different aspects of the business have been impacted by COVID-19, and how it is navigating rising costs.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In this article we presented the 10 medical technology stocks to buy. You can skip our detailed discussion on these stocks, and read the 5 Medical Technology Stocks to Buy. The unprecedented COVID-19 pandemic disrupted the world’s largest industries, including manufacturing, airlines, restaurants, and oil and gas drilling, but the medical technology sector has gone […]